Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 2/20 | 0.41 |
| ▸ | POLG | P54098 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.32 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846489 | 0.92 | POLB (0.46) | SLC22A6POLA1POLGABCB11FAP | |
| SCHEMBL15531905 | 0.92 | SLC22A6 (0.40) | SLC22A6POLA1POLGABCB11FAP | |
| SCHEMBL6846396 | 0.91 | SLC22A6 (0.39) | SLC22A6POLA1POLGABCB11FAP | |
| Alamifovir SCHEMBL4971117 | 0.91 | SLC22A6 (0.40) | SLC22A6POLA1POLGABCB11FAP | |
| Alamifovir SCHEMBL29388338 | 0.91 | SLC22A6 (0.40) | SLC22A6POLA1POLGABCB11FAP | |
| SCHEMBL6847969 | 0.87 | SLC22A6 (0.40) | SLC22A6POLA1POLGABCB11FAP | |
| SCHEMBL6846424 | 0.85 | FGFR1 (0.53) | SLC22A6POLA1POLGPOLBFGFR1 | |
| SCHEMBL14295938 | 0.84 | POLB (0.43) | SLC22A6POLA1POLGABCB11FAP | |
| SCHEMBL6840916 | 0.84 | FAP (0.42) | FAPCYP2C19CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12149448 | 0.82 | SLC29A1 (0.51) | SLC22A6POLA1POLGABCB11FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767900-B2 | VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-27 | — | — | US | claimed |
| US-20030153534-A1 | Phosphonate nucleotide compound | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-14 | — | — | US | claimed |
| US-6767900-B2 | VIRICIDES AGAINST HERPES, HUMAN IMMUNODEFICIENCY, HEPATITIS, CYTOMEGALO AND VARICELLA- ZOSTER VIRUSES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-07-27 | — | — | US | disclosed |
| US-20030153534-A1 | Phosphonate nucleotide compound | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
| WO-2003028737-A1 | ANTI-VIRAL AGENTS AND IN-VITRO METHOD FOR THE IDENTIFICATION OF CANDIDATES ABLE TO INHIBIT BINDING OF POLYMERASE TO EPSILON | MITSUBISHI PHARMA CORPORATION (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153534-A1 | Phosphonate nucleotide compound | TYMP, PNP, MTAP | SLC22A6 451/4885POLA1 277/4885POLG 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.